{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016131","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.338219+00:00","generated_at":"2026-05-21T22:48:12.191186+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CervoMed posts Q1 net loss $4.9M, secures $50M ATM facility; reports positive Phase 2b DLB results","bullets":["Entered $50M at-the-market offering agreement with Leerink Partners; 3% commission on sales.","Cash and marketable securities $35.2M at March 31, 2025, down from $38.9M at Dec 31, 2024; runway into mid-2026.","Net loss $4.9M for Q1 2025 compared to $2.5M in Q1 2024, driven by higher R&D costs for neflamapimod.","Sixteen-week extension data from RewinD-LB Phase 2b showed CDR-SB improvement (p<0.001 vs old capsules, p=0.003 vs placebo); Phase 3 planned in mid-2026.","Initiating Phase 2a trials in primary progressive aphasia (mid-2025) and ischemic stroke recovery (recently started)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016131","json":"https://secwatch.observer/filing/0001437749-25-016131.json","markdown":"https://secwatch.observer/filing/0001437749-25-016131.md","text":"https://secwatch.observer/filing/0001437749-25-016131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/0001437749-25-016131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/crvo20250509_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T22:48:12.191186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}